Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotech company focused on developing first-in-class targeted and immune-mediated cancer therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management will engage in a fireside chat on Tuesday, December 3, 2024 at 9:00 a.m. ET. Interested parties can access both live and archived recordings of the discussion through the investor section of Tempest's website at ir.tempesttx.com.
Tempest Therapeutics (Nasdaq: TPST), un'azienda biotech in fase clinica focalizzata nello sviluppo di terapie oncologiche mirate e mediate dal sistema immunitario, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. Il senior management dell'azienda parteciperà a una chiacchierata informale martedì 3 dicembre 2024 alle 9:00 a.m. ET. Le parti interessate possono accedere sia alle registrazioni dal vivo che a quelle archiviate della discussione attraverso la sezione per investitori del sito web di Tempest all'indirizzo ir.tempesttx.com.
Tempest Therapeutics (Nasdaq: TPST), una empresa biotecnológica en etapa clínica enfocada en desarrollar terapias contra el cáncer dirigidas y mediadas por el sistema inmunológico, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La alta dirección de la empresa participará en una charla distendida el martes 3 de diciembre de 2024 a las 9:00 a.m. ET. Las partes interesadas pueden acceder tanto a las grabaciones en vivo como a las archivadas de la discusión a través de la sección para inversionistas del sitio web de Tempest en ir.tempesttx.com.
템페스트 테라퓨틱스 (Nasdaq: TPST)는 1급 표적 및 면역 매개 암 치료제를 개발하는 임상 단계의 생명공학 회사로, 파이퍼 샌들러 제36회 연례 의료 회의에 참가한다고 발표했습니다. 회사의 고위 경영진은 2024년 12월 3일 화요일 오전 9시 ET에 파이어사이드 챗에 참여할 예정입니다. 관심 있는 분들은 템페스트 웹사이트의 투자자 섹션(ir.tempesttx.com)을 통해 논의의 생중계 및 아카이브 녹음을 모두 접속할 수 있습니다.
Tempest Therapeutics (Nasdaq: TPST), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies ciblées et médiées par le système immunitaire contre le cancer, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. La direction de l'entreprise participera à une discussion informelle le mardi 3 décembre 2024 à 9h00 ET. Les personnes intéressées peuvent accéder aux enregistrements en direct et archivés de la discussion via la section investisseurs du site web de Tempest à l'adresse ir.tempesttx.com.
Tempest Therapeutics (Nasdaq: TPST), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von erstklassigen zielgerichteten und immunvermittelten Krebstherapien konzentriert, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Das Senior Management des Unternehmens wird am Dienstag, den 3. Dezember 2024 um 9:00 Uhr ET an einem informellen Gespräch teilnehmen. Interessierte Parteien können sowohl Live- als auch Archivaufzeichnungen der Diskussion über den Investorenbereich der Webseite von Tempest unter ir.tempesttx.com abrufen.
- None.
- None.
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that members of senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 9:00 a.m. ET.
To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
_______________________________
i If approved by the FDA
FAQ
When is Tempest Therapeutics (TPST) presenting at the Piper Sandler Healthcare Conference 2024?
How can investors access Tempest Therapeutics' (TPST) Piper Sandler Conference presentation?
What type of presentation will TPST give at the Piper Sandler Healthcare Conference 2024?
What is the focus of Tempest Therapeutics' (TPST) drug development program?
